GlassScriptPhysician profile
Yudhishtra Markan
NPI 1891762019
$18,450.78
in general payments reported to CMS, 2019-2025
83 companies · $2,564 in 2025
The $2,564 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,794 · 2020: $672 · 2021: $2,144 · 2022: $2,019 · 2023: $3,290 · 2024: $1,968 · 2025: $2,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,820 · Long Term Medical Supply Or Device Loan: $565 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,820.38 |
| Long Term Medical Supply Or Device Loan | $565.46 |
| Education | $436.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,012.63 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $1,608.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,543.24 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Daiichi Sankyo INC. | $811.60 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Janssen Biotech, INC. | $706.74 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Amgen INC. | $694.72 | 2019-2023 | Lumakras, Xgeva, Kyprolis |
| Merck Sharp & Dohme LLC | $620.90 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $481.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $473.97 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Genentech USA, INC. | $408.30 | 2019-2025 | Venclexta, Phesgo, Tecentriq |
| Lilly USA, LLC | $407.50 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $367.30 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $333.34 | 2019-2025 | |
| Gilead Sciences, INC. | $309.68 | 2019-2025 | Trodelvy |
| Celgene Corporation | $271.11 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yudhishtra Markan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.